Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | UNG | P13051 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530060 | 0.98 | ALDH1A1 (0.47) | ALDH1A1KMT2APARP10PARP3ADRB2 | |
| SCHEMBL10810727 | 0.84 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL22173530 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KMT2APARP10PARP3ADRB2 | |
| SCHEMBL17907572 | 0.81 | NPC1 (0.42) | KMT2AADRB2ADRB1ADRB3MAPT | |
| SCHEMBL6307975 | 0.81 | MAPT (0.40) | ALDH1A1KMT2AMAPT | |
| SCHEMBL8948561 | 0.81 | TPMT (0.38) | — | |
| SCHEMBL6754862 | 0.80 | MAPK1 (0.46) | ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL16553458 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KMT2APARP10PARP3ADRB2 | |
| SCHEMBL28665174 | 0.78 | ALDH1A1 (0.61) | ALDH1A1KMT2APARP10PARP3ADRB2 | |
| SCHEMBL15515208 | 0.78 | ELANE (0.46) | ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 589 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2018-09-20 | — | — | US | claimed |
| EP-2494075-B1 | TEMPLATED NANOCONJUGATES | UNIV NORTHWESTERN (US) | 2018-04-04 | — | — | EP | claimed |
| EP-2714752-B1 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | AMICUS THERAPEUTICS INC (US) | 2017-11-22 | — | — | EP | claimed |
| WO-2015032981-A1 | ERYTHROPOIETIN CONJUGATES HAVING ORAL BIOAVAILABILITY | LEK PHARMACEUTICALS D.D. (SI) | 2015-03-12 | — | — | WO | claimed |
| EP-2227243-B1 | A PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE | HANMI SCIENCE CO LTD (KR) | 2014-08-13 | — | — | EP | claimed |
| US-8263084-B2 | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate | HANMI SCIENCE CO., LTD (KR) | 2012-09-11 | — | — | US | claimed |
| EP-2494075-A2 | TEMPLATED NANOCONJUGATES | Northwestern University (US) | 2012-09-05 | — | — | EP | claimed |
| US-20110257375-A1 | INCREASING EFFICIENCY OF NUCLEIC ACID DELIVERY IN VIVO USING TARGETING CONJUGATES | BIOO SCIENTIFIC CORPORATION | 2011-10-20 | — | — | US | claimed |
| EP-2341916-A1 | COLOSTRUM COMPOSITION | Nanoko A/S (DK) | 2011-07-13 | — | — | EP | claimed |
| EP-2249661-A2 | PRODUCTS AND METHODS TO PREVENT INFECTION | Multimerics APS (DK) | 2010-11-17 | — | — | EP | claimed |
| WO-2010128793-A2 | FAT SOLUBLE VITAMIN AND A DERIVATIVE THEREOF INDUCED BY NOVEL CATIONIC CHITOSAN, A METHOD OF PRODUCING SAME AND DRUG DELIVERY SYSTEM CONTAINING SAME | 고려대학교 산학협력단 (KR) | 2010-11-11 | — | — | WO | claimed |
| EP-2227243-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE | Hanmi Pharmaceutical Co., Ltd. (KR) | 2010-09-15 | — | — | EP | claimed |
| US-20100069814-A1 | SYSTEM AND METHOD FOR UTILIZING MICROBUBBLES AND LIPOSOMES AS VIRAL SEQUESTERING AGENTS | VERUS BIOTECHNOLOGY CORPORATION | 2010-03-18 | — | — | US | claimed |
| WO-2010028652-A1 | COLOSTRUM COMPOSITION | NANOKO A/S (DK) | 2010-03-18 | — | — | WO | claimed |
| US-20100003701-A1 | COVALENT MODIFICATION AND CONJUGATION OF LUCIFERASE | CARDIOGENICS INC. (CA) | 2010-01-07 | — | — | US | claimed |
| US-20090311698-A1 | DIAGNOSTIC ASSAY | WAYNE STATE UNIVERSITY | 2009-12-17 | — | — | US | claimed |
| WO-2009092383-A2 | PRODUCTS AND METHODS TO PREVENT INFECTION | MULTIMERICS APS (DK) | 2009-07-30 | — | — | WO | claimed |
| WO-2009069983-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2009-06-04 | — | — | WO | claimed |
| US-20070254311-A1 | Covalent modification and conjugation of luciferase | CARDIOGENICS INC. (CA) | 2007-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | ALDH1A1 3685/4885KMT2A 2178/4885PARP10 701/4885 |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ALDH1A1 3966/4885KMT2A 573/4885PARP10 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.